[EN] GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE<br/>[FR] INHIBITEURS DE GLYCOLATE OXYDASE POUR LE TRAITEMENT D'UNE MALADIE
申请人:BIOMARIN PHARM INC
公开号:WO2020257487A1
公开(公告)日:2020-12-24
Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with a defect in glyoxylate metabolism, for example a disease or disorder associated with the enzyme glycolate oxidase (GO) or alterations in oxalate metabolism. Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.
ruthenium(II)‐catalyzed deoxygenative transfer hydrogenation of amides to amines using HCO2H/NEt3 as the reducing agent is reported for the first time. The catalyst system consisting of [Ru(2‐methylallyl)2(COD)], 1,1,1‐tris(diphenylphosphinomethyl) ethane (triphos) and Bis(trifluoromethane sulfonimide) (HNTf2) performed well for deoxygenative reduction of various secondary and tertiary amides into the corresponding
首次报道了使用HCO 2 H / NEt 3作为还原剂的钌(II)催化的酰胺脱氧转移胺成胺。催化剂体系由[Ru(2-甲基烯丙基)2(COD)],1,1,1-三(二苯基膦甲基)乙烷(triphos)和双(三氟甲烷磺酰亚胺)(HNTf 2)在将各种仲酰胺和叔酰胺脱氧还原成相应的胺方面表现出色,选择性极好,并且对包括还原敏感基团在内的官能团表现出很高的耐受性。氢源和酸助催化剂的选择对于催化至关重要。机理研究表明,通过借入氢对原位生成的醇和胺进行还原胺化是主要途径。
[EN] ISOINDOLINE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER<br/>[FR] COMPOSÉS D'ISOINDOLINE UTILISABLES DANS LE CADRE DU TRAITEMENT DU CANCER
申请人:CELGENE CORP
公开号:WO2010053732A1
公开(公告)日:2010-05-14
Provided herein are isoindoline compounds such as those of formula (I), pharmaceutical compositions comprising one or more of such compounds, and methods of their use for treating, preventing, or managing various diseases. Formula (I)
Indole, indazole and indoline derivatives as CETP inhibitors
申请人:Conte-Mayweg Aurelia
公开号:US20060030613A1
公开(公告)日:2006-02-09
The present invention relates to compounds of formula (I):
wherein —X—Y—, R
1
to R
11
and n are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prevention of diseases which are mediated by CETP inhibitors.
An insecticidal composition comprising, in admixture with an agriculturally acceptable carrier, an insecticidally effective amount of a compound of the formula: ##STR1## wherein R, R.sup.1, R.sup.2, R.sup.3, R.sup.7, R.sup.8, m, n, and p are as defined herein, and agriculturally acceptable salts thereof, and methods of using the same.